Principia Biopharma Inc (PRNB) Forecast, Price Target & Analyst Ratings

NASDAQ:PRNB

Current stock price

100.05
+0.1 (+0.1%)
At close:
100.02
-0.03 (-0.03%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Principia Biopharma Inc (PRNB).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release Date
N/A

ChartMill Buy Consensus

Rating
82.80%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $100.05 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

Analyst Ratings & History

Current Analyst Ratings

PRNB Current Analyst RatingPRNB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

PRNB Historical Analyst RatingsPRNB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.80%
PRNB was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PRNB.
In the previous month the buy percentage consensus was at a similar level.
PRNB was analyzed by 7 analysts. More opinions would make the average more meaningful.

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

Principia Biopharma Inc / PRNB Forecast FAQ

What is the number of analysts for PRNB stock?

The number of analysts covering Principia Biopharma Inc (PRNB) is 7.